BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34321240)

  • 21. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
    Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
    Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mir142 loss unlocks IDH2
    Marshall A; Kasturiarachchi J; Datta P; Guo Y; Deltcheva E; James C; Brown J; May G; Anandagoda N; Jackson I; Howard JK; Ghazaly E; Brooks S; Khwaja A; Araki M; Araki K; Linch D; Lord GM; Enver T; Nimmo R
    Sci Rep; 2020 Nov; 10(1):19390. PubMed ID: 33173219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1.
    Pineault N; Buske C; Feuring-Buske M; Abramovich C; Rosten P; Hogge DE; Aplan PD; Humphries RK
    Blood; 2003 Jun; 101(11):4529-38. PubMed ID: 12543865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis.
    Xu H; Valerio DG; Eisold ME; Sinha A; Koche RP; Hu W; Chen CW; Chu SH; Brien GL; Park CY; Hsieh JJ; Ernst P; Armstrong SA
    Cancer Cell; 2016 Dec; 30(6):863-878. PubMed ID: 27889185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depletion of cytotoxic T-cells does not protect NUP98-HOXD13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect.
    Gough SM; Chung YJ; Aplan PD
    PLoS One; 2012; 7(5):e36876. PubMed ID: 22606303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
    Chen C; Liu Y; Lu C; Cross JR; Morris JP; Shroff AS; Ward PS; Bradner JE; Thompson C; Lowe SW
    Genes Dev; 2013 Sep; 27(18):1974-85. PubMed ID: 24065765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.
    Slape C; Lin YW; Hartung H; Zhang Z; Wolff L; Aplan PD
    J Natl Cancer Inst Monogr; 2008; (39):64-8. PubMed ID: 18648006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiling of precursor T-cell lymphoblastic leukemia/lymphoma identifies oncogenic pathways that are potential therapeutic targets.
    Lin YW; Aplan PD
    Leukemia; 2007 Jun; 21(6):1276-84. PubMed ID: 17429429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
    Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
    Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
    Zou Y; Zeng Y; Zhang DF; Zou SH; Cheng YF; Yao YG
    Biochem Biophys Res Commun; 2010 Nov; 402(2):378-83. PubMed ID: 20946881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
    Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
    Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice.
    Cheng X; Byrne M; Brown KD; Konopleva MY; Kornblau SM; Bennett RL; May WS
    Blood; 2015 Sep; 126(13):1585-94. PubMed ID: 26202421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A unique mutator phenotype reveals complementary oncogenic lesions leading to acute leukemia.
    Yin M; Baslan T; Walker RL; Zhu YJ; Freeland A; Matsukawa T; Sridharan S; Nussenzweig A; Pruitt SC; Lowe SW; Meltzer PS; Aplan PD
    JCI Insight; 2019 Dec; 4(23):. PubMed ID: 31622281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH1 and IDH2 mutations in pediatric acute leukemia.
    Andersson AK; Miller DW; Lynch JA; Lemoff AS; Cai Z; Pounds SB; Radtke I; Yan B; Schuetz JD; Rubnitz JE; Ribeiro RC; Raimondi SC; Zhang J; Mullighan CG; Shurtleff SA; Schulman BA; Downing JR
    Leukemia; 2011 Oct; 25(10):1570-7. PubMed ID: 21647154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.
    Kernytsky A; Wang F; Hansen E; Schalm S; Straley K; Gliser C; Yang H; Travins J; Murray S; Dorsch M; Agresta S; Schenkein DP; Biller SA; Su SM; Liu W; Yen KE
    Blood; 2015 Jan; 125(2):296-303. PubMed ID: 25398940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia.
    Ashraf S; Noguera NI; Di Giandomenico J; Zaza S; Hasan SK; Lo-Coco F
    Ann Hematol; 2013 Oct; 92(10):1319-23. PubMed ID: 23949315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
    Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities.
    Cardin S; Bilodeau M; Roussy M; Aubert L; Milan T; Jouan L; Rouette A; Laramée L; Gendron P; Duchaine J; Decaluwe H; Spinella JF; Mourad S; Couture F; Sinnett D; Haddad É; Landry JR; Ma J; Humphries RK; Roux PP; Hébert J; Gruber TA; Wilhelm BT; Cellot S
    Blood Adv; 2019 Nov; 3(21):3307-3321. PubMed ID: 31698461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A NUP98-HOXD13 leukemic fusion gene leads to impaired class switch recombination and antibody production.
    Puthiyaveetil AG; Heid B; Reilly CM; HogenEsch H; Caudell DL
    Exp Hematol; 2012 Aug; 40(8):622-33. PubMed ID: 22613470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors.
    Zuurbier L; Gutierrez A; Mullighan CG; Canté-Barrett K; Gevaert AO; de Rooi J; Li Y; Smits WK; Buijs-Gladdines JG; Sonneveld E; Look AT; Horstmann M; Pieters R; Meijerink JP
    Haematologica; 2014 Jan; 99(1):94-102. PubMed ID: 23975177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.